coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Cheadle Network PCN, Stockport (LAD) · Health Inequalities Profile

    PCN U56857 · NHS Greater Manchester Integrated Care Board · 4 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    36,597

    Registered population

    57.8% aged 18–64

    20.3%

    Aged 65+

    ICB 14.9% · England 17.9%

    5.7%

    In IMD quintile 1

    ICB 40.7% · England 21.0%

    ~2,231

    Core20 residents (est.)

    Resident basis; registered basis ~2,226 · see page 3

    5,997

    Hypertension register

    +5.25% in 3 yrs · England +5.60%

    349

    SMI register

    10.4% of Stockport (LAD)'s

    526

    COPD register

    Reviews +0.22% in 3 yrs

    Forecast to 2030

    6,861

    Hypertension patients, 2030

    +864 on today

    68.3%

    QRISK ≥20% on statins, 2030

    +2.78pp over 3 yrs

    5.0%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    15.1%
    Deprivation concentrates at Cheadle Medical Practice.

    Cheadle Medical Practice holds a 15.1% Core20 share (1,801 estimated patients) vs 0.0% at Gatley Medical Centre, alongside a 14.4 pp phone access range.

    67.1%
    Heart failure and asthma reviews trail comparators.

    Heart failure reviews fell 7.2% over 2023 to 2025 to 67.1% (England 78.5%), and about 840 asthma patients lack a review, which may reflect.

    72.8%
    Hypertension control and SMI checks exceed England.

    Hypertension treatment to target reaches 72.8% (England 70.3%), BP monitoring is 92.2% (England 90.0%), and SMI annual BP checks reach 87.9% (England 83.4%).

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    A dual-peaked age profile is consistent with higher youth and older adult demand

    Cheadle Network PCN registers 36,597 patients with a dual-peaked age profile. Children aged 0-17 comprise 22.0% (8,044 patients), exceeding Stockport (LAD) (19.7%), NHS Greater Manchester Integrated Care Board (21.8%), and England (19.6%). Older adults aged 65+ represent 20.3% (7,419 patients), above Stockport (LAD) (19.7%), the ICB (14.9%), and England (17.9%). Working-age adults (18-64) account for 57.8% (21,134 patients). Census-recorded Gypsy or Irish Traveller residents are 0.0% and Roma residents 0.1%. Observation periods were not supplied for list counts.

    Age profile

    0–1722.0%
    18–6457.8%
    65+20.3%

    65+: ICB 14.9%, England 17.9%

    Older people · falls rows are Stockport (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Stockport LA)2,0722,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)84.5%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)57.8%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Stockport LA)9191,0219552024/25
    Falls deaths, all ages, per 100,000 (Stockport LA)23.718.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Deprivation averages decile 7.3 but Core20 share reaches 15.1% at Cheadle Medical Practice

    Average IMD decile is 7.3 (Stockport (LAD) 6.4, England 5.5). The Core20 share—patients in England's most deprived 20%—is 5.7% (England 21.0%). Deprivation is concentrated: Cheadle Medical Practice holds 15.1% Core20 share (estimated 1,801 patients), whereas Gatley Medical Centre records 0.0% (Finney Lane Surgery 3.5%, Heald Green Health Centre 2 2.4%). Weighted practice share (6.1%) differs by 0.34 pp from the PCN rate, and resident estimates (about 2,200) use a different base; periods are unstated. Outreach should focus primarily where Core20 volume concentrates.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Cheadle Medical15.1% · 1,801 patients
    Finney Lane3.5% · 243 patients
    Heald Green 22.4% · 182 patients
    Gatley0.0% · 0 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    349

    SMI register

    0.96% recorded prevalence

    208

    Learning disability register

    0.57% recorded prevalence

    11

    Care homes, 527 beds

    In the PCN catchment

    9.5%

    Provide unpaid care

    Stockport (LAD), Census 2021

    Severe mental illness records 349 patients (1.0%) and learning disabilities 208 (0.6%), both matching England (1.0% and 0.6%). In the catchment area, 11 care homes contain 527 beds, though bed capacity does not establish resident numbers. Stockport borough context includes 48 rough sleepers in 2025 and an estimated ceiling of 3,477 unpaid carers.

    Severe mental illness: physical health checks

    SMI blood pressure checks reached 87.9% (England 83.4%) and BMI recording reached 86.1% (England 82.1%). However, BMI recording fell 0.7 pp over 2023 to 2025 (England +5.1 pp), and Cheadle Medical Practice recorded 76.0%.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    5,997

    Hypertension register

    +5.25%

    Register growth, 3 yrs

    Stockport (LAD) +4.99% · England +5.60%

    +2.35pp

    BP control, under 80

    ≤140/90 · +2.44pp aged 80+

    +864

    More patients by 2030

    Forecast 6,861 (18.23%)

    Hypertension case-finding and control

    Recorded hypertension prevalence is 16.5% across 5,997 patients, compared with 16.2% in Stockport (LAD), 14.4% in the ICB, and 15.2% in England. Blood pressure checks reach 92.2% (England 90.0%) and treatment to target reaches 72.8% (England 70.3%). Across 477 heart failure patients (prevalence 1.3%), annual reviews including functional capacity assessment fell 7.2% over 2023 to 2025 (England +8.7%) to 67.1%, trailing Stockport (LAD) (79.3%), the ICB (80.0%), and England (78.5%). Denominators include personalised care adjustments, and crude prevalence does not establish unmet need. Hypertension management exceeds national benchmarks, but heart failure review rates trail all comparators, so prioritising structured heart failure recalls is the key clinical opportunity.

    Lipids and statins

    Lipid therapy for QRISK ≥ 20% reaches 62.3%, below Stockport (LAD) (64.8%), the ICB (67.0%), and England (63.6%). Primary-prevention statins in diabetes fell 2.8% over 2023 to 2025 (England +2.1%) to 70.6% (England 73.2%). Fewer at-risk patients receive lipid-lowering therapy than benchmarks imply, making targeted primary-prevention recall the operational priority.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 202668,587£2.20£1.94£1.86£150,891
    Cardiovascular (all), 202596,838£2.97£3.15£3.33£287,609

    In 2026, 68,587 items of lipid-regulating drugs were prescribed (spend £150,891) at £2.20 per item, exceeding Stockport (LAD) (£1.99), the ICB (£1.94), and England (£1.86). The PCN spent £23,320 more than at England's unit cost across 68,587 items. This metric reflects unit cost rather than efficiency; formulary reviews would test prescribing choices.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    −1.26%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    −3.50%

    Asthma prevalence, PCN 3-yr % change

    COPD prevalence is 1.4% (526 patients), below England (1.9%) and Stockport (LAD) (2.1%), and fell 6.5% over 2023 to 2025 while England grew +2.6% (unadjusted gap +167 to +259 patients). COPD reviews reach 77.4% (England 76.4%). Asthma prevalence is 7.1% (2,406 patients), but annual reviews fell 1.3% over 2023 to 2025 to 65.1% (England 65.7%), leaving about 840 patients unreviewed. Youth asthma second-hand smoke recording is 72.1% (England 78.8%). Register audits would test potential case-finding gaps.

    Cancer register and children's immunisation

    Cancer prevalence is 4.5% (1,655 patients), above England (3.8%) and Stockport (LAD) (4.4%), though growth (+5.2%) lagged England (+9.0%) over 2023 to 2025. In Q1 2025/26, 6-in-1 coverage at 12 months is 88.9% (below the 95.0% target by 6.1 pp). At age 5, MMR dose 1 is 95.6% and dose 2 is 93.0%, while 4-in-1 booster coverage is 86.8% (below the 95.0% target by 8.2 pp).

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months88.9%

    England 91.0%

    6-in-1 complete primary course at 24 months95.7%

    England 92.2%

    MMR dose 1 at 24 months93.5%

    England 88.3%

    MMR dose 2 at age 593.0%

    England 82.8%

    4-in-1 pre-school booster at age 586.8%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.6%

    Greater Manchester ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,270

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Greater Manchester ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%15%2,193
    Prostate61.7%53.2%14%1,788
    Breast82.5%85.4%19%1,758
    Bowel46.3%47.0%19%1,427
    Skin cancer84.5%87.8%27%580

    In 2022, across NHS Greater Manchester ICB, 55.6% of cancers with a known stage (6,491 of 11,679) were diagnosed at stage 1 or 2 (England 55.3%), with a distance of -19.4 pp to the 75.0% national ambition by 2028. Staging coverage was 70.8% (11,679 of 16,492 cancers; England 67.0%). Reaching the ambition requires about 2,270 additional early-stage cases annually across the ICB. While ICB staging reflects wider system performance rather than PCN delivery, PCN cervical screening coverage is 74.2% (Stockport (LAD) 75.9%, England 66.8%), after falling 7.2% over 2023 to 2025 (England -1.0%). Slower screening uptake could delay early cancer diagnosis; recall audits would test local booking barriers.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    In Jul 2026 (provisional), provider Manchester University NHS Foundation Trust achieved 72.8% on the cancer 62-day referral to treatment standard (Stockport NHS Foundation Trust 74.7%, Northern Care Alliance NHS Foundation Trust 78.6%, NHS Greater Manchester Integrated Care Board 75.7%, England 71.2%), with a distance of -12.2 pp to the 85.0% standard. Cancer 28-day faster diagnosis reached 80.1% (Stockport NHS Foundation Trust 83.2%, ICB 79.5%, England 79.3%), exceeding the 75.0% standard by 5.1 pp. Diagnostic waits of 6+ weeks at the trust reached 14.7% for CT and 11.7% for MRI (Stockport NHS Foundation Trust 2.9% and 1.4%).

    Pathways within standard (%)ManchesterStockportNorthern Care AllianceGreater Manchester ICBEngland
    28-day faster diagnosis (75%)80.0683.2175.2079.5379.32
    31-day treatment (96%)92.5497.3994.5496.4992.50
    62-day referral to treatment (85%)72.8574.6778.6575.7371.16
    Diagnostic waits over 6 weeks (%)ManchesterStockportNorthern Care AllianceEngland
    MRI11.681.415.0921.40
    CT14.662.934.109.92
    Echocardiography4.9117.4631.4828.48
    Colonoscopy4.515.5340.0430.83
    Gastroscopy29.355.3136.4829.02
    All 15 DM01 tests8.9814.0815.7123.14
    Community services activityStockport residentsGreater Manchester ICB
    Care contacts57,085573,310
    Referrals10,69094,470
    Patients with a contact16,950183,535

    Community services (residents of Stockport), Jun 2026 (provisional). In Jun 2026 (provisional), 60.6% of community contacts among Stockport borough residents were with adults aged 65+ (34,585 of 57,085 contacts). This reflects wider borough community service utilisation rather than PCN-level activity, as PCN-specific community contacts were not captured.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Practice variation and patient experience

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Gatley1480.068.3%70.1%87.1%
    Finney Lane1093.558.3%84.3%85.4%
    Cheadle Medical10215.153.9%66.3%78.8%
    Heald Green 21302.455.7%72.2%78.1%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNStockport (LAD)AssetPCNStockport (LAD)
    Care homes (catchment)11 (527 beds)n/aSchools (catchment)49n/a
    Children's centresno data2Places of worship27135
    Libraries212Food banks (VCS)n/a1
    Primary schools (LA maintained)1261Primary academies223
    Special schools34

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Structured asthma annual review recall

    Asthma review coverage is 65.1% (England 65.7%, ICB 66.2%, Stockport (LAD) 63.4%) after falling 1.3% (0.8 pp) over 2023 to 2025, leaving about 840 of 2,406 patients unreviewed. For discussion: run a single-template asthma recall with flexible or school-holiday slots and inhaler prescribing checks. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    COPD case-finding and spirometry audit

    COPD prevalence is 1.4% (526 patients vs England 1.9%, Stockport (LAD) 2.1%, ICB 2.3%) after falling 6.5% over 2023 to 2025; unadjusted gap is +167 to +259 across 36,597 patients. Moderate effort to run.

    Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.

    Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.

    Option 3

    Heart failure and lipid recall

    Heart failure reviews fell 7.2% over 2023 to 2025 to 67.1% (England 78.5%, Stockport (LAD) 79.3%; 477 register, 1.3%). QRISK ≥ 20% lipid therapy is 62.3% (England 63.6%) and diabetes statins 70.6% (England 73.2%). Moderate effort to run.

    Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.

    Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Targeted Core outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    SMI annual check recall (p4)Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs)MHIS · From Harm to HopePCN
    Heart failure annual review audit (p5)Patients with heart failure who had a review in the last 12 months including the assessment of functional capacity (denominator incl. PCAs)—PCN
    Preschool booster recall audit (p6)4-in-1 pre-school booster (DTaP/IPV) coverage at age 510YHP sickness to prevention · 95% targetPCN
    Cervical screening recall audit (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Practice telephony and triage review (p9)GPPS easy to contact the practice by phone10YHP, hospital to communityPractice
    Option 1 · Structured asthma annual review recall (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN
    Option 2 · COPD case-finding and spirometry audit (p12)COPD register · COPD: QOF prevalence · Registered populationCore20PLUS5 approach · Tobacco and Vapes BillPCN
    Option 3 · Heart failure and lipid recall (p12)Heart failure register · Heart Failure: QOF prevalence · Patients with heart failure who had a review in the last 12 months including the assessment of functional capacity (denominator incl. PCAs)NHS Long Term Plan (diabetes) and National Diabetes AuditPCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15